Allogeneic CAR T Company Prepares to Widen Access to Patients
An allogeneic CAR T-cell therapy company is planning a pivotal Phase III randomized-control trial, hoping their products can reach more patients and help those who can’t access autologous therapies. The post Allogeneic CAR T Company Prepares to Widen Access to Patients appeared first on GEN - Genetic Engineering and Biotechnology News .
We haven't written up this one. GEN Biotechnology has the full story — the link below goes straight to it.
